GYRE (Gyre Therapeutics) Property, Plant and Equipment: $23.6 Mil (As of Mar. 2026)


GYRE Gyre Therapeutics Inc GYRE
43 GF Score
Price $7.36
GF Value $9.81
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Gyre Therapeutics Property, Plant and Equipment?

Gyre Therapeutics GYRE +12.58% 43 Property, Plant and Equipment is $23.6 Mil as of Mar. 2026. GuruFocus rates GYRE with a GF Score™ of 43/100 and a GF Value™ of $9.81 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Gyre Therapeutics's quarterly net PPE increased from Sep. 2025 ($23.6 Mil) to Dec. 2025 ($24.7 Mil) but then declined from Dec. 2025 ($24.7 Mil) to Mar. 2026 ($23.6 Mil).

Gyre Therapeutics's annual net PPE increased from Dec. 2023 ($23.8 Mil) to Dec. 2024 ($25.7 Mil) but then declined from Dec. 2024 ($25.7 Mil) to Dec. 2025 ($24.7 Mil).


Gyre Therapeutics  (NAS:GYRE) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Gyre Therapeutics Property, Plant and Equipment Related Terms


Gyre Therapeutics Property, Plant and Equipment Historical Data

* Premium members only.

The historical data trend for Gyre Therapeutics's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics Property, Plant and Equipment Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Property, Plant and Equipment
17.34 18.38 23.78 25.70 24.73

Gyre Therapeutics Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.52 23.40 23.61 24.73 23.57
GYRE
43GF Score
Gyre Therapeutics Inc GYRE
Property, Plant and Equipment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gyre Therapeutics Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.

What does a Property, Plant and Equipment of $23.6 Mil mean?
Gyre Therapeutics (GYRE) has a Property, Plant and Equipment of $23.6 Mil as of Mar. 2026. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Gyre Therapeutics and its competitors.
Is Gyre Therapeutics' Property, Plant and Equipment too high?
Gyre Therapeutics' current Property, Plant and Equipment is $23.6 Mil. Overall, Gyre Therapeutics has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Property, Plant and Equipment compare to RLMD and ACRS?
Gyre Therapeutics' Property, Plant and Equipment of $23.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Property, Plant and Equipment for a Biotechnology company?
A good Property, Plant and Equipment depends on the Biotechnology industry context. However, Property, Plant and Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Property, Plant and Equipment mean?
A high Property, Plant and Equipment can signal that a stock is expensive relative to its fundamentals. The total property, plant and equipment recorded on a company's balance sheet less accumulated depreciation. View historical data on Gyre Therapeutics and its competitors. Gyre Therapeutics's current Property, Plant and Equipment is $23.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Modestly Undervalued. The stock's GF Value™ is $9.81, compared to a current price of $7.36 — trading 25% below its estimated fair value. The current Property, Plant and Equipment is $23.6 Mil. Gyre Therapeutics' overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Property, Plant and Equipment calculated?
Property, Plant and Equipment is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Property, Plant and Equipment is $23.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gyre Therapeutics (GYRE) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of $7.36 is trading 25% below its estimated GF Value™ of $9.81. GuruFocus considers Gyre Therapeutics to be Modestly Undervalued.

Key valuation signals for GYRE:

  • Property, Plant and Equipment: $23.6 Mil
  • GF Value™: $9.81 vs. price of $7.36 (25% below fair value)
  • GF Score™: 43/100 with 2 warning signs

No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gyre Therapeutics Business Description

Other Exchanges L9S:Germany
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
43GF Score

Get the complete analysis for GYRE

Property, Plant and Equipment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.36
Price
$9.81
GF Value